Table 3.
Pathways and genes more frequently altered in anaplastic thyroid cancer than in differentiated thyroid cancer.
| Gene or group of genes | Prevalence, %
|
p-value* | |
|---|---|---|---|
| DTC | ATC | ||
| Tumor suppressors | 21 | 74 | 1.45e-38 |
| TP53 | 11 | 65 | 2.77e-50 |
| NF2 | 2 | 12 | 4.26e-06 |
| RB1 | 2 | 7 | 0.01 |
| NF1 | 3 | 9 | 0.01 |
|
| |||
| Cell cycle pathway | 13 | 29 | 7.42E-10 |
| CDKN2A | 7 | 22 | 4.29E-06 |
| CDKN2B | 4 | 13 | 0.001 |
| CCNE1 | 0 | 4 | 0.001 |
|
| |||
| PI3K/AKT pathway | 18 | 37 | 9.50E-06 |
| PIK3CA | 5 | 14 | 0.002 |
| PTEN | 4 | 11 | 0.01 |
|
| |||
| SWI/SNF nucleosome modification pathway | 9 | 18 | 0.007 |
| PBRM1 | 1 | 4 | 0.01 |
|
| |||
| Immune evasion | 2 | 5 | 0.07 |
| CD274 | 0 | 3 | 0.03 |
| PDCD1LG2 | 0 | 4 | 0.01 |
| JAK2 | 1 | 4 | 0.03 |
|
| |||
| Hedgehog signaling pathway | 0 | 3 | 0.009 |
|
| |||
| Histone modification | 11 | 19 | 0.03 |
|
| |||
| Mutation-high genotype | 2 | 6 | 0.05 |
|
| |||
| RAC1 | 0 | 4 | 0.004 |
|
| |||
| KIT | 0 | 4 | 0.004 |
| KDR | 0 | 3 | 0.03 |
| PDGFRA | 0 | 3 | 0.03 |
|
| |||
| INPP4B | 0 | 3 | 0.009 |
|
| |||
| NFE2L2 | 0 | 3 | 0.03 |
|
| |||
| CASP8 | 0 | 3 | 0.03 |
|
| |||
| EPHA3 | 1 | 4 | 0.03 |
|
| |||
| NBN | 0 | 3 | 0.03 |
Signaling pathways and groups of genes are highlighted in bold.
*
- χ2, p-values were adjusted for multiple comparisons using Benjamini-Hotchberg method.